| pubmed-article:6247399 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6247399 | lifeskim:mentions | umls-concept:C0521026 | lld:lifeskim |
| pubmed-article:6247399 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:6247399 | lifeskim:mentions | umls-concept:C0018442 | lld:lifeskim |
| pubmed-article:6247399 | lifeskim:mentions | umls-concept:C1998793 | lld:lifeskim |
| pubmed-article:6247399 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6247399 | pubmed:dateCreated | 1980-8-25 | lld:pubmed |
| pubmed-article:6247399 | pubmed:abstractText | The minimal molecular requirements for elicitation of secondary anti-Sendai virus CTL were investigated. The hemagglutinin-neuraminidase (HN) glycoprotein of Sendai virus and the H-2Kk glycoprotein of YAC tumor cells were purified and incorporated into phospholipid vesicles. These unilamellar liposomes were then tested for the ability to elicit H-2 restricted secondary anti-Sendai virus CTL. The results indicate that these well-defined vesicles were capable of eliciting secondary anti-Sendai virus CTL which lysed only target cells possessing the H-2Kk haplotype and modified with inactivated Sendai virus. | lld:pubmed |
| pubmed-article:6247399 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6247399 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:6247399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6247399 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6247399 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:6247399 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:6247399 | pubmed:author | pubmed-author:HaleA HAH | lld:pubmed |
| pubmed-article:6247399 | pubmed:author | pubmed-author:HarrisD TDT | lld:pubmed |
| pubmed-article:6247399 | pubmed:author | pubmed-author:RuebushM JMJ | lld:pubmed |
| pubmed-article:6247399 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6247399 | pubmed:volume | 125 | lld:pubmed |
| pubmed-article:6247399 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6247399 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6247399 | pubmed:pagination | 428-30 | lld:pubmed |
| pubmed-article:6247399 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:meshHeading | pubmed-meshheading:6247399-... | lld:pubmed |
| pubmed-article:6247399 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:6247399 | pubmed:articleTitle | Elicitation of anti-viral cytotoxic T lymphocytes with purified viral and H-2 antigens. | lld:pubmed |
| pubmed-article:6247399 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6247399 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6247399 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6247399 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6247399 | lld:pubmed |
